Immunomodulatory effects of extracellular vesicles in glioblastoma

Johannes Jun Wei Low, Siti Aishah Sulaiman, Nor Adzimah Johdi and Nadiah Abu*

UKM Medical Molecular Biology Institute (UMBI), UKM Medical Centre, Universiti Kebangsaan Malaysia, Jalan Ya’acob Latiff, Bandar Tun Razak, Kuala Lumpur, Malaysia

Glioblastoma (GB) is a type of brain cancer that can be considered aggressive. Glioblastoma treatment has significant challenges due to the immune privilege site of the brain and the presentation of an immunosuppressive tumor microenvironment. Extracellular vesicles (EVs) are cell-secreted nanosized vesicles that engage in intercellular communication via delivery of cargo that may cause downstream effects such as tumor progression and recipient cell modulation. Although the roles of extracellular vesicles in cancer progression are well documented, their immunomodulatory effects are less defined. Herein, we focus on glioblastoma and explain the immunomodulatory effects of extracellular vesicles secreted by both tumor and immune cells in detail. The tumor to immune cells, immune cells to the tumor, and intra-immune cells extracellular vesicles crosstalks are involved in various immunomodulatory effects. This includes the promotion of immunosuppressive phenotypes, apoptosis, and inactivation of immune cell subtypes, which affects the central nervous system and peripheral immune system response, aiding in its survival and progression in the brain.

KEYWORDS: glioma, exosome, immune cells, Tumor microenvironment, microvesicle (MV)

Introduction

Central nervous system (CNS) cancers comprise both primary and secondary CNS tumors in which the former are derived from CNS cells while the latter emerges from the spread of cancerous cells from the peripheral body to the brain (Lapointe et al., 2018; Achrol et al., 2019). The incidence rate for secondary CNS tumors is expected to be larger than primary CNS tumors (Davis et al., 2012), with the survival rate determined by the primary cancer location (Cagney et al., 2017). Nevertheless, the low incidence rate of primary CNS cancer is confounded by its high mortality rate (Miller et al., 2021). Gliomas, representing only 24.5% of all primary brain and CNS tumors, hold 80.9% of recorded malignant tumors, signifying the importance of this cancer as a modern-day killer (Ostrom et al., 2021). Currently, both glioblastoma, isocitrate dehydrogenase-wildtype (IDH-wildtype) and astrocytoma, IDH-mutant (previously glioblastoma, IDH-mutant) are classified as WHO Grade 4. Astrocytoma, IDH-mutant is a highly malignant
astrocytic glioma with a low survival rate (6.8% survival rate post-diagnosis, median survival of 8 months) and portrayed mutations to either IDH1/2 (Louis et al., 2021; Ostrom et al., 2021). It was previously mentioned that glioblastoma emerges in two different types: 1) primary, in which it arises de novo, or 2) secondary, where it progresses from a lower grade astrocytoma (Oghaki and Kleihues, 2013) but following the 2021 classification, the term “secondary glioblastoma” which commonly involves R132H mutation in IDH1 (92.7% of various brain tumors) was annulled (Balsi et al., 2008; Louis et al., 2021). Glioblastoma (GB) arises de novo with a very fast progression rate (mean 6.3 months from the first symptom to definitive diagnosis) (Oghaki and Kleihues, 2005; Oghaki and Kleihues, 2007). Growth dynamics analysis conducted by Stensjøen et al. showed that untreated GB has a median specific growth rate of 1.4% every day, leading to an equivalent volume doubling time of 49.6 days, further showcasing the expedited growth of GB tumors (Stensjøen et al., 2015). GB tumors need to mediate an immunosuppressive microenvironment (Brown et al., 2018) through bidirectional communication with surrounding resident cells via several approaches including soluble factors, direct cell–cell contact, and extracellular vesicles (Broekman et al., 2018), where the latter is increasingly recognized as an important mediator of cell-cell communication (Gao et al., 2020).

The CNS is traditionally known as an “immune privileged” site due to several factors, including 1) the presence of a blood-brain barrier (BBB) that limits access to peripheral immune cells, 2) the lack of a lymphatic vessel serving the CNS which limits antigen trafficking and presentation in lymph nodes, 3) paucity of antigen-presenting cells (APC) in the CNS, 4) downregulation of major histocompatibility complex (MHC) expression in normal brain parenchyma leading to diluted T cell immune response, and 5) presence of anti-inflammatory modulators (Fabry et al., 2008; Brown et al., 2018). The CNS facilitates the entry and continued presence of immune cells to survey and respond against foreign entities such as tumors (Papadopoulos et al., 2020). Still, GB has long been considered a “cold” tumor with high intrinsic and adaptive resistance to immunotherapy (Jackson et al., 2019) due to intratumoral heterogeneity and lack of high-quality neoantigens, as well as severe dysregulation of immune cells favoring the immunosuppressive phenotype (Hao et al., 2002). Nevertheless, efforts have been taken to convert the “cold” GB phenotype to a more immunotherapy-susceptible “hot” phenotype (Tomaszewski et al., 2019). Glioma cells often engage with multiple glial cell types, including immune cells, to create an immunosuppressive tumor microenvironment (TME) via the secretion of pro-tumorigenic mediators (Quail and Joyce, 2017; Brown et al., 2018). Mechanisms relating to immune cells’ response in the GB microenvironment remain scarce and incompletely defined (Lim et al., 2018) although extracellular vesicles are found to be implicated in several instances stated further along in this review.

**Extracellular vesicles**

EVs are small lipid-enclosed membrane vesicles secreted from virtually all kinds of cells into the extracellular spaces to engage in various cellular processes (Urabe et al., 2020). EVs can be classified based on their size: small EVs consist of particles <200 nm in diameter, medium EVs consist of particles between 200–400 nm in diameter, and large EVs consist of particles larger than 400 nm in diameter (Théry et al., 2018). Tumor cells-derived EVs play important roles in modulating the tumor microenvironment (TME) and promoting tumor progression via the transfer of tumor-specific molecules to recipient cells (Ricklefs et al., 2016). Effects of this intercellular communication include the establishment of a premetastatic niche, promoting angiogenesis, disruption to the peritoneum or BBB, chemotherapeutic drug resistance, and formation of heterogeneous cancer-associated fibroblast (Urabe et al., 2020). Several studies have also described the variety of cargo carried within the vesicle including proteins and nucleic acids in both small and large EVs (Thakur et al., 2014; Hurwitz et al., 2016; García-Romero et al., 2017; Vagner et al., 2018). In essence, EVs allow biomolecules to be transported in a stable and protected format, allowing liquid biopsy utilizing patients’ blood. García-Romero et al. reported on the presence of glioma tumor-derived genomic DNA (gDNA) despite the presence of the BBB, denoting EV’s capability to bypass the anatomical restriction (García-Romero et al., 2017).

Biomolecules present in and on the extracellular vesicles are representative of parental cells and are often functional (Yekula et al., 2020). A study conducted by Kucharzewska et al. demonstrated that exosomes reflect the hypoxic status of glioma cells evidently through the cargo makeup of the exosome (Kucharzewska et al., 2013). Exosomal enzymes’ mRNA levels correspond to levels in parental cells, further denoting the presence of an elaborate cargo selection machinery in cells (Shao et al., 2015). Several mechanisms have been determined to influence cargo selection in EVs, notably the ADP-ribosylation factor 6 (ARF-6)-Exportin-5 axis, where ARF6-GTP interacts with Exportin-5 to deliver mRNA into tumor microvesicles (MVs) in an ARF6-GTP dependent manner (Clancy et al., 2019). Other than that, target proteins can also be sorted into EVs via ubiquitination, which is mainly mediated by endosomal sorting complexes required for transport (ESCRT) complex and partly by other proteins displaying Ubiquitin (Ub)-binding domains (Piper et al., 2014). Lipid sorting is not well understood, but Bissig and Gruenberg (Bissig and Gruenberg, 2013) summarized several important factors such as lipid-lipid/lipid-protein interaction, differing membrane biophysical traits, and
metabolic enzyme turnover rate/distribution to be deeply involved with differing lipid populations in endosomes (Bissig and Gruenberg, 2013). Various other cargoes can also get sorted into exosomes via post-translational modifications (Moreno-Gonzalo et al., 2018). The schematic representation of GB-derived EVs immunosuppression is described in Figure 1.

EV is also instrumental in the metabolism modulation within the GB TME. Tumor-activated stromal cells (TASC), also known as cancer-associated fibroblasts have been determined to transfer mitochondria to primary GB cells via various mechanisms including EVs (Salaud et al., 2020). This led to increased glycolysis which translates to better GB proliferation (Salaud et al., 2020). Under favorable metabolic conditions, GB cells also utilize EVs as a vehicle to reduce intracellular miRNA content. This is evident when GB cells secrete exosomal miR-451, which is >40-fold more abundant in EVs compared to in cells (Van Der Vos et al., 2016). Although said EVs were absorbed by microglia, the increased release of exosomal miR-451 from GB cells coincides with a GB cell self-preservation mechanism when glucose is limited. Godlewski et al. (Godlewski et al., 2010) demonstrated when glucose is limited, miR-451 levels in the cell decline, leading to heightened CAB39 expression, activation of AMPK and consequently cell survival by reducing cell proliferation. GB-derived EVs are also capable of modulating other cells in the CNS to facilitate the TME. A
| Donor cells | Types of EV | Participating molecules | Receptor cells | Role/Function | References |
|-------------|-------------|-------------------------|----------------|--------------|------------|
| Tregs       | Exosomes    | miR-150–5p, miR-142–3p  | Dendritic cells | miR-150–5p, miR-142–3p mediated induction of tolerogenic phenotype in DCS, leading to increased IL-10 and decreased IL-6 production following LPS stimulation | Tung et al. (2018) |
| Fork2+ T regulatory (Treg) cells | Exosome | Various miRNAs | Effector T cell | Treg-mediated immunosuppression via secretion of miRNA-containing exosomes | Okoye et al. (2014) |
| Tregs       | EV          | miR-150–5p and miR-142–3p | Dendritic cells | GBM-derived EVs release PD-L1+ EVs and induce the formation of MDSC and PD-1+ NCM | Himes et al. (2020) |
| GB          | EV          | PD-L1                  | T cells, monocytes, dendritic cells | GBM-derived EVs release PD-L1+ EVs and induce the formation of MDSC and PD-1+ NCM | Himes et al. (2020) |
| Glioma      | Exosomes    | -                      | Peripheral monocytes, CD8+ T lymphocytes | Promotion of immunosuppressive HLA-DR+ mononuclear phenotypes; glioma-derived exosomes lacked antigen-presentation machinery and surface co-modulatory molecules | Iorgulescu et al. (2016) |
| Glioma      | EVs, particularly exosomes | Wilms tumor-1 (WT-1) | Microglia | Glioma-derived EVs promote tumor progression by affecting microglial gene expression and promoting microglial recruitment and angiogenesis; WT1 in EVs downregulates microglial Tbias1 gene expression | Tsutsui et al. (2020) |
| Glioma cells | EV          | miR-21                | Microglia | EV-derived miR-21 is functionally transferred from glioma to microglia through EVs in vivo, mediating reprogramming of microglia in the tumor microenvironment through increased post-852 downregulation | Abels et al. (2019) |
| Hypoxia glioma | Exosomes | miR-10a, miR-21       | MDSC | MDSC expansion and activation via RORA and PTEN silencing | Guo et al. (2018) |
| Glioma stem cell | Exosomes | -                      | PBMCs, CD4+ monocyte | GSC-derived exosomes and exosomes from GBM peripheral blood suppress the peripheral T-cell immune response by acting on monocyte maturation rather than on direct interaction with T cells, skewing them toward a monocyte-MDSC tumor-supportive phenotype | Domenis et al. (2017) |
| GB          | Serum exosomes and cytokines | -                      | Normal monocytes | M2-like monocytes expressing CD14+ and CD163 are elevated in GB patient blood, indicating Th2 bias | Harshyne et al. (2016) |
| GB          | EV          | miR-451/miR-21         | Microglia | Microglia avidly took up GB-EVs, causing increased proliferation and shifting their cytokine profile toward immune suppression | Van Der Vos et al. (2016) |
| GB, GSC     | EV          | GSC: CSPG4, PTGFRN and DHP2B GB: α2M, EDIL3, and HBB. Shared: CSPG4, α2M, MFGE8 (lactadherin), EGFR and different types of integrins | Peripheral blood-derived monocytes, Microglia | GB EVs promote differentiation of peripheral blood-derived monocytes into M2 macrophages, induced changes to cell surface protein expression, cytokine secretion and increased phagocytic capacity; induced microglia to be tumor supportive | De Vrij et al. (2015) |
| Glioma      | EV          | -                      | Monocytes | Glioma EV |
|             |             |                        |               | • Increased SOCS3 expression in monocytes |
|             |             |                        |               | • Decreased MHCI, CD80 expression |
|             |             |                        |               | • Increased PD-L1, Ly6C expression |
|             |             |                        |               | • Increased suppressive cytokines and immune mediators’ expression (IL-10, TGFβ, arginase, iNOS) |
|             |             |                        |               | • Production of monocytes, causing decreased activated CD4+ T cell proliferation | Luong et al. (2021) |
study by Oushy et al. (Oushy et al., 2018) found that GB EV-treated normal human astrocytes (NHA) displayed enhanced migration ability and cytokine production, which are tumor-promoting phenotypes favored by GBM cells. The EV-mediated NHA drive to tumor-supporting phenotype was further elucidated by Hallal et al. (Hallal et al., 2019) when it was postulated that EV-treated NHA displayed a senescence-associated secretory profile (SASP) along with enhanced migration capabilities through enhanced podosome and gelatin matrix degradation. EV-mediated cell modulation in the GBM TME also occurs in immune cells, where tumor-associated macrophages (TAMs) are found to secrete CHD7-targeting microRNAs to glioma stem cells (GSCs) to trigger a proneural-to-mesenchymal transition (PMT) (Zhang et al., 2020). As PMT confers resistance to therapy, this contributes to worsening diagnosis in recurrent GBM (Fedele et al., 2019). Other than that, GSCs-derived EVs also induce the growth of brain endothelial cells (BEC), further enhancing their survival (Spinelli et al., 2018) which may be beneficial to the GBM TME. A study comparing glioma-derived human ECs (GhECs) and normal human ECs (NhECs) determined that GhEC-EV significantly induced LN229 GB cell line migration in vitro via MYO1C transfer to recipient cells (Tian et al., 2020). A study by Lucero et al. (Lucero et al., 2020) also discovered that GSC-derived EVs carry vasculature-associated miRNAs that reprogram brain EC to perform angiogenesis. EC is also vital for the formation of the blood–brain barrier (Kadry et al., 2020) yet a study by Treps et al. (Treps et al., 2016) discovered that Semaphorin3A expressed on GBM EVs’ surface causes increased vascular permeability in vivo, which can jeopardize the integrity of the BBB. GSC also secrete VEGF-A, a known angiogenic and permeability factor in the exosomal form to human BECs (Treps et al., 2017).

Immunotherapy-based strategies for GB have shown some preclinical successes that were not translated into Phase 3 clinical efficacies. (Yu and Quail, 2021). Therefore, looking into the TME might provide clues to targeting this issue. A paper by Ali et al. (Ali et al., 2021) showed that TME-targeting treatments including combination strategies led to a variety of post-treatment GB TME. GB cells have been shown to utilize extracellular vesicles (EVs) to circumvent immunotherapies and radiation therapy. For instance, U87 glioma cell line treated with bevacizumab has been shown to secrete out EVs containing bevacizumab on the surface (Simon et al., 2018) albeit with a slight influence on cell viability and proliferation in clinical dosages. Hypoxic glioma cells also secrete exosomal miR-301a that promotes resistance to radiotherapy (Yue et al., 2019). In terms of metabolism, the post-irradiation brain allows a tumor-tolerant microenvironment via metabolic shift with high production of energy carriers and low production of antioxidants (Gupta et al., 2020), which might also be translated into extracellular vesicles as well. This has been documented when GB cell lines of multiple subtypes exposed to either acute or chronic irradiation also exhibit metabolic changes that translate into the alteration of microvesicle cargo, ultimately modulating said vesicles’ paracrine signaling towards untreated glioma cells (Baulch et al., 2016).

Radiation therapy and chemotherapy might also cause glioma cells to be more malignant. U87MG cells exposed to radiation also secrete more exosomes with enhanced cell migration capability due to an increased abundance of cell motility-related mRNA and proteins (Arscott et al., 2013). Pavlyukov et al. (Pavlyukov et al., 2018) also demonstrated that apoptotic cell-derived EVs (apoEVs) from irradiated or chemo-treated glioma cells promote malignancy by phenotypic changes induced by splicing factor transfer to recipient glioma cells. A study by Ramakrishnan et al. (Ramakrishnan et al., 2020) also demonstrated that irradiation causes glioma cells to adopt a stem cell state by EV-mediated release of miR-603, causing resistance to ionizing radiation and DNA alkylating drugs. In terms of chemotherapy, temozolomide administered to glioma stem cells also induce secretion of GSC-derived EVs that are enriched with cell adhesion proteins which might aid in tumor progression (Andre-Gregoire et al., 2018). TMZ-induced EV cargo change is also reported by Garnier et al. (Garnier et al., 2018) when they determined that EVs secreted by GB cell lines contained TMZ resistance transcripts. A comprehensive study by Cuperlovic-Culf et al. (Cuperlovic-Culf et al., 2020) on GB cell line-derived EVs also showed that metabolome cargoes are implicated in immune response and metabolism amid being varied depending on the cell line.

### Crosstalk between extracellular vesicles and T cells

T cells’ secretion of EVs is documented to be upregulated post T cell receptor (TCR) triggering, which possibly mediates surface TCR/CD3-mediated cell homing (Blanchard et al., 2002).
Other than that, overactive T cells are also capable of secreting Fas ligand (FasL) and Apo2 ligand (APO2L) via EV release, suggesting EV-mediated autocrine or paracrine immune regulation (Monléon et al., 2001). Delivery of specific cargo to recipient cells is also evident with mechanisms including sequence motifs-dependent microRNA localization into exosomes (Villarroya-Beltri et al., 2013) and monophosphorylation-dependent FasL sorting into secreted lysosomes (Zuccato et al., 2007). Nevertheless, death ligands need to be bound on the membrane to crosslink sufficiently with their corresponding death receptors (Anel et al., 2019).

In general, T cells EVs deliver cargoes such as enzymes, transmembrane proteins, members of the immunoglobulins (Ig) superfamily, and MHC molecules to target cells such as APCs (Choudhuri et al., 2014; Mittelbrunn et al., 2011; Nolte-’t Hoen et al., 2004) and B cells (Yang et al., 2019). Multiple responses in target cells were recorded, including activation-induced cell death (AICD) where microvesicles containing FasL and APO2L were released shortly before cell apoptosis (Martínez-Lorenzo et al., 1999). Positive and negative regulation of T cell responses were also recorded. T cell-derived EVs carry surface receptors and molecules to APCs, causing transcellular signaling and modulation of APCs (Choudhuri et al., 2014; Nolte-’t Hoen et al., 2004). T cell-derived exosomes are also capable of transporting miRNA to APCs, causing changes to recipient cells’ gene expressions (Mittelbrunn et al., 2011).

Tregs, owning to their immunosuppressive traits, also secrete exosomes that perform similar functions. Immunosuppression mediated by Tregs involves several different mechanisms, including adenosine (Ado) mediated immunomodulation (Smyth et al., 2013; Schuler et al., 2014), cyclooxygenase-2 (Cox-2) mediated regulation of interferon-gamma (IFNγ) secretion in T effector cells (Okoye et al., 2014), target cell cycle arrest and apoptosis, conversion of T cells into Tregs (Aiello et al., 2017), induction of tolerogenic dendritic cells (DCs) (Tung et al., 2018), and increased resistance to apoptosis by Tregs cells (Czysztowska et al., 2010). GB cell line-derived exosomes contain inhibitory proteins such as CD39, FasL, CTLA-4, TRAIL, and CD73 that attenuate the normal function of all immune cells (Azambuja et al., 2020). GB has been documented to release PD-L1+ EVs which inhibit T cell proliferation via myeloid-derived suppressor cells (MDSC) and nonclassical monocytes (NCM) instead of direct T cell inhibition (Himes et al., 2020). The mechanism of action is in contrast to findings by Ricklefs et al. who argue GB-derived EVs block TCR-mediated T cell activation (Ricklefs et al., 2018), although Hines et al. do point out the possible discrepancy with T cell stimulation employed by both researchers causing contrasting results regarding GB EVs role (Himes et al., 2020).

GB-derived exosomes have limited ability to activate CD8+ T lymphocytes (Iorgulescu et al., 2016) yet it has been reported that the expression of CD86 on glioma cell lines can be bound competitively by cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), leading to possible T cell immunosuppression (Walker and Sansom, 2011). Therefore, more research is needed to elucidate the GB-derived EV effect on T cells. The crosstalk between EVs and T cells, and other immune cells are tabulated in Table 1.

**Effects of extracellular vesicles on myeloid cells**

Given myeloid cells’ extensive presence in the brain, gliomas’ interaction with them is considerably more frequent, where up to 30% of total glioma/glioblastoma mass is comprised of myeloid cells (Arcuri et al., 2017). Gliomas utilize this concentration of myeloid cells to their advantage by secreting EVs capable of modulating microglia. The WT-1 protein is found secreted in glioma-derived EVs and downregulates thrombospondin-1 (Tb1s1) in microglia, subsequently promoting angiogenesis which is vital in glioma progression (Wagner et al., 2014; Tsutsui et al., 2020). Other than that, microglia proliferation is also promoted via downregulation of BTG anti-proliferation factor 2 (Btg2) expression in microglia post-delivery of miR-21 through EVs (Abels et al., 2019).

Glioma cells also exhibit EV-mediated malignancy under hypoxic conditions. Under hypoxic conditions, glioma cells secrete exosomes containing TERF2 interacting protein (TERF2IP) targeting-miR-1246, causing activation and inhibition of STAT3 and Nuclear factor-xB (NF-xB) signaling pathways respectively. This leads to the polarization of macrophages from M1 to immunosuppressive M2 phenotype (Qian et al., 2020). Glioma cells under hypoxic conditions have also been found to secrete exosomes containing miR-10a and miR-21 to MDSCs, causing its expansion and activation (Guo et al., 2018), which further exacerbates cancer progression via inhibition of immune cell functions, Tregs expansion and promotion of immunosuppressive regulatory B cells (Bregs) (Mi et al., 2020). Other than that, GB affects T-cell immune response through the modulation of monocytes. Systemic T cell suppression via glioma stem cells (GSCs) derived exosomes occurs with internalization by CD14+ monocytes which causes stunted maturation and formation of monocytic MDSCs, subsequently disrupting CD3+ and CD4+ T cell activation (Domenis et al., 2017). GB EVs also induces the proliferation of NCMs and MDSCs, eventually inhibiting T cell proliferation (Himes et al., 2020).

GB is also able to influence the peripheral immune environment via exosomes as M2-like monocytes expressing CD163 and CD14 are highly expressed in the GB patients’ peripheral blood, representing a Th2 bias (Harshyne et al., 2016). GB tumors also secrete miR-451 and miR-21 in EVs, which when internalized by microglia, cause an increase in microglia proliferation and a cytokine shift favoring immune suppression (Van Der Vos et al., 2016). GB EVs also contain
leukocyte migration and focal adhesion-specific proteins that skewed peripheral monocytes' differentiation towards M2 macrophages in addition to modification to macrophages' cell surface protein expression, cytokine secretion, and phagocytic effect (De Vrij et al., 2015). De Vrij et al. also mentioned human microglia exhibit high expression of membrane-type 1-matrix metalloproteinase (MT1-MMP) post-incubation with GB EVs, which supports tumor growth, denoting the tumor proliferation aspect of cancer-associated immune cells in addition to their immunoregulatory role (De Vrij et al., 2015). Luong et al. (Luong et al., 2021) also determined that glioma-derived EVs perform several pro-tumorigenic functions in monocytes such as upregulated expression of suppressive cytokines, PD-L1 and lymphocyte antigen six complex (Ly6C), downregulation of expression of suppressive cytokines, proteins, PD-L1 and pro-tumorigenic functions in monocytes such as upregulated expression of suppressive cytokines, proteins, PD-L1 and lymphocyte antigen six complex (Ly6C), downregulation of expression of proinflammatory cytokines, MHC II and costimulatory CD80 expression as well as the conversion of monocytes into suppressive cells involved in inhibition of activated CD8+ T cells (Luong et al., 2021). IFN-γ stimulation of GB cells also causes superinduction of GB-derived, immunosuppressive IDO-1 and PD-L1 expressing EVs, which led to immunosuppression of monocytes on top of differentiation of monocytes into immunosuppressive MDSCs and NCMs (Jung et al., 2022).

**Effects of extracellular vesicles on NK cells**

NK cells are also known to secrete extracellular vesicles containing a variety of biomolecules, including membrane and extracellular matrix (ECM) proteins (tetraspanins, integrins), death receptor ligands, cytolytic enzymes, and miRNA that translate into cytotoxic effect in cancer cells such as apoptosis while avoiding damage to normal PBMCs (Farcas and Inngjerdingen, 2020). Other than that, NK extracellular vesicles (NKEVs) cause immunomodulation in PBMCs including higher expression of HLA-DR and costimulatory molecules on monocytes, CD25 on T cells, and CD56 on NK cells, which translates into both pro-inflammation and anti-inflammation spectrum of the immune response (Federici et al., 2020). NK exosomes also contain Fasl, Natural Killer Group 2D (NKG2D), and perforin molecules, which perform an individualistic function: perforin mediates tumor and activated immune cell death in a time and dose-dependent manner, while Fas is suggested to be involved in lymphocyte homeostasis regulation (Lugini et al., 2012). NKG2D, typically known as an activating receptor by cytolytic lymphoid cells (Pende et al., 2001), typically can induce a cytolytic effect without more specific natural cytotoxicity NK receptors, yet their functional role in exosomes is not known. Activated NKEVs induced dose-dependent caspase-mediated apoptosis in neuroblastoma via functional perforin, granulysin, and granzymes A and B mediation of the caspase pathway (Jong et al., 2017) which possibly translates into a similar result in GB. As per other immune cells, tumor-derived MVs secreted under hypoxic conditions are more potent in impairing NK cytotoxicity and cell function as compared to normoxic equivalent (Berchem et al., 2016) due to the delivery of CD107a targeting-miR23a and TGF-β (Alter et al., 2004; Viel et al., 2016). NK EVs are also multifaceted in immunomodulation. Azambuja et al. mentioned that GB-derived exosomes suppress NK cell activation by suppressing NKG2D expression levels (Azambuja et al., 2020). In contrast to this, NK cells also secrete cytotoxic EVs under the influence of pro-inflammatory cytokines (Enomoto et al., 2021) with IL-15 and IL-21 both playing significant roles in NK cell activation (Carson et al., 1994; Skak et al., 2008). All in all, studies have shown that NK cell activity can be modulated by tumor-derived EVs, including those of GB origin, with the effect dependent on external stimuli such as the balance between immune promoting- and inhibiting-signals, further confirming the notion that NK cell function is niche dependent.

**Effects of extracellular vesicles on B cells**

B cell's secretion of EVs has been documented with the release of MHC II-containing exosomes (Raposo et al., 1996), which it was suggested to involve in antigen presentation (Lindenbergh and Stoorvogel, 2018). Muntasell et al. reported on upregulated B cell-derived exosome carrying antigen-antipeptide MHC II (pMHC II) by the antigen-specific CD4+ T cell, which can poise as a positive modulator for ongoing immune response and maintenance of antigenic memory in T cells (Muntasell et al., 2007). Given so, B cells exosomes are also implicated in anti-inflammatory responses such as the possible transfer of membrane-tethered CD73 to Tregs in the peripheral causing an increase in anti-inflammatory adenosine secretion (Schuler et al., 2014). A more recent paper by Zhang et al. also demonstrated that CD19+ EVs secreted from B cells induce hydrolysis of adenosine triphosphate (ATP) to adenosine via incorporated CD39 and CD73 action, thus inhibiting CD8+ T cell proliferation and subsequent reduction in chemotherapy efficacy (Zhang et al., 2019). Although both studies do not employ GB as their model, the GB tumor microenvironment is known to be hypoxic (Brown et al., 2018; Tomaszewski et al., 2019), and CD73 is found to be upregulated in both CNS (Kulesskaya et al., 2013) and hypoxic conditions (Li et al., 2006). B cells in the CNS might also participate in the upregulation of adenosine, especially when Zhang et al. also mentioned that hypoxia-inducible factor-1α (HIF-1α) mediated Rab27a expression causes heightened EV secretion by B cells (Zhang et al., 2019). Glioma cells also participated in B cell modulation. Glioma cells secrete placental growth factor (PIGF) in exosomal form, which in contact with naïve B cells can induce their differentiation to Bregs (Han et al., 2014). Induced Bregs suppress granzyme B and perforin secretion by the glioma-specific CD8+ T cell, denoting specificity in B cell action against glioma. However, relevant publications regarding B cells exosome against glioma are still lacking.
Conclusion

In conclusion, EVs play vital roles in both faces of the immunopathological aspects of GB. EVs typically reflect the physiological state of the donor cell and perform specific effector functions in recipient cells, thus modulating the recipient cells to have an abnormal phenotype. This plays well into the induction of the TME, which in the GB context involves the relationship between GB tumors and neighboring cells, promoting immunosuppression within the brain. How the common cell adjusts its metabolic requirement to fit into the objective of the tumor microenvironment is an interesting avenue to research, especially among the usage of EVs, which can be a vehicle for both paracrine and endocrine signaling in the signaling in the first place. More thorough EV research across all facets of cell biochemistry is needed to synthesize, elucidate, and magnify possible influential pathways in the cell, where such results can be translated into more optimized and effective screening and treatment strategies in the future.

Author contributions

NA wrote the initial draft, JW wrote the manuscript, NA, SS and NJ edited the manuscript.

References

Abels, E. R., Maas, S. L. N., Nieland, L., Wei, Z., Cheah, P. S., Tai, E., et al. (2019). Glioblastoma-associated microglia reprogramming is mediated by functional transfer of extracellular miR-21. Cell Rep. 28, 3105–3119. doi:10.1016/j.celrep.2019.08.036

Achrol, A. S., Rennert, R. C., Anders, C., Soffietti, R., Ablinwalia, M. S., Nayak, L., et al. (2019). Brain metastases. Nat. Rev. Dis. Prim. 5, 5. doi:10.1038/s41572-018-0055-y

Aiello, S., Rocchetta, F., Longaretti, L., Faravelli, S., Todeschini, M., Cassis, L., et al. (2017). Extracellular vesicles derived from T regulatory cells suppress T cell proliferation and prolong allograft survival. Sci. Rep. 7, 11518–11519. doi:10.1038/s41598-017-08617-3

Ali, S., Borin, T. F., Pirazimuthu, A., Ara, R., Lebedyeva, J., Angara, K., et al. (2021). Changes in the tumor microenvironment and outcome for TME-targeting therapy in glioblastoma: A pilot study. PLoS One 16, e0246646. doi:10.1371/journal.pone.0246646

Alter, G., Malemfort, J. M., and Altfeld, M. (2004). CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 294, 15–22. doi:10.1016/j.jim.2004.08.008

André-Gregoire, G., Bidere, N., and Gavard, J. (2018). Temsolomade affects extracellular vesicles released by glioblastoma cells. Biochimia 155, 11–15. doi:10.1016/j.bchm.2018.02.007

Anel, A., Gallego-Lleyda, A., de Miguel, D., Naval, J., and Martínez-Lostao, L. (2019). Role of exosomes in the regulation of T-cell mediated immune responses and in autoimmune disease. Cells 8, 154. doi:10.3390/cells08020154

Arcuri, C., Fioretti, B., Bianchi, R., Mecca, C., Tubaro, C., Beccari, T., et al. (2017). Microglia-glioma cross-talk: A two way approach to new strategies against glioma. Front. Biosci. 22, 268–309. doi:10.2741/4486

Ascott, W. T., Tandle, A. T., Zhao, S., Shabason, J. E., Gordon, I. K., Schlaff, C. D., et al. (2013). Ionizing radiation and glioblastoma exosomes: implications in tumor biology and cell migration. Transl. Oncol. 6, 638–648. doi:10.1016/j.tranon.2013.06

Azambuja, J. H., Ludwig, N., Zerreni, S., Rao, A., Braganhol, E., and Whiteside, T. L. (2020). Molecular profiles and immunomodulatory activities of glioblastoma-derived exosomes. Neuro Oncol. Adv. 2, vdaa056–11. doi:10.1093/noajnl/vdaa056

Bals, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., and von Deimling, A. (2008). Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 116, 597–602. doi:10.1007/s00401-008-0455-2

Baulch, J. E., Geidzinski, E., Tran, K. K., Yu, L., Zhou, Y. H., and Limoli, C. L. (2016). Irradiation of primary human gliomas triggers dynamic and aggressive survival responses involving microvesicle signaling. Environ. Mol. Mutagen. 57, 405–415. doi:10.1002/em.21988

Berchem, G., Noman, M. Z., Bossell, M., Paggetti, J., Baconnais, S., Le cam, E., et al. (2016). Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF-β and miR23a transfer. Oncotargets Immunol. 5, e1062968. doi:10.1080/2162402X.2015.1062968

Bissig, C. and Grunenberg, J. (2013). Lipid sorting and multivesicular endosome biogenesis. Cold Spring Harb. Perspect. Biol. 5, a016816. doi:10.1101/cshperspect.a016816

Blanchard, N., Lankar, D., Faure, F., Regnault, A., Dumont, C., Raupo, G., et al. (2002). TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/ζeta complex. J. Immunol. 168, 3235–3241. doi:10.4049/jimmunol.168.7.3235

Broekman, M. L., Maas, S. L. N., Abels, E. R., Mempel, T. R., Krichovsky, A. M., and Breakefield, X. O. (2018). Multidimensional communication in the microenvironment of glioblastoma. Nat. Rev. Neuro. 14, 482–495. doi:10.1038/nrneurol.2018.018-0025-8

Brown, N. F., Carter, T. J., Ottaviani, D., and Mulholland, P. (2018). Harnessing the immune system in glioblastoma. Br. J. Cancer 119, 1171–1181. doi:10.1038/s41416-018-0258-8

Cagney, D. N., Martin, A. M., Catalano, P. J., Redig, A. J., Lin, N. U., Lee, E. Q., et al. (2017). Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: A population-based study. Neuro. Oncol. 19, 1511–1521. doi:10.1093/neuonc/nox077

Carson, W. E., Giri, J. G., Lindemann, M. J., Sinon, L. M., Ahluwalia, M. S., Nayak, L., et al. (2002). TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/ζeta complex. J. Immunol. 168, 32353241. doi:10.4049/jimmunol.168.7.3235

Carson, W. E., Giri, J. G., Lindemann, M. J., Sinon, L. M., Ahluwalia, M. S., Nayak, L., et al. (2002). TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/ζeta complex. J. Immunol. 168, 3235–3241. doi:10.4049/jimmunol.168.7.3235

Choudhuri, K., Llodra, J., Roth, E. W., Tsai, J., Gordo, S., Wucherpfennig, K. W., et al. (2014). Polarized release of T-cell-receptor-enriched microvesicles at the immunological synapse. Nature 507, 118–123. doi:10.1038/nature12951

Funding

JW was funded by the HiCoE grant JJ-2021–003. Parts of the figure were produced using pictures “Monocytes” from Servier Medical Art, provided by Servier, licensed under a Creative Commons Attribution 3.0 unported license.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Evidence of Th1, Th2 and Th3 cytokine dysregulation. Acta Neuropathol. 103, 171–178. doi:10.1007/s004010010448

Harshyne, L. A., Nasca, B. J., Kenyon, L. C., Andrews, D. W., and Hooper, D. C. (2016). Serum exosomes and cytokines promote a T-helper cell type 2 environment in the peripheral blood of glioblastoma patients. Neuro Oncol. 18, 206–215. doi:10.1093/neuroonc/nov107

Himes, B. T., Peterson, T. E., de Mooki, T., Garcia, I. M. C., Jung, M. Y., Uhlm, S., et al. (2020). The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppression. Neuro Oncol. 22, 967–978. doi:10.1093/neuonc/noaa29

Harwitz, S. N., Rider, M. A. B., Bundy, J. L., Liu, X., Singh, R. K., and Meckes, D. G. (2016). Proteomic profiling of NCI 60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers. Oncotarget 7, 86999–87015. doi:10.18632/oncotarget.13569

Jorgelusca, J. B., Ivan, M. E., Safaee, M., and Parsa, A. T. (2016). The limited capacity of malignant glioma-derived exosomes to suppress peripheral immune effectors. J. Neurooncol. 290, 103–108. doi:10.1007/s11060-015-1102-4

Jackson, C. M., Choi, J., and Lim, M. (2019). Mechanisms of immunotherapy resistance. Lessons from glioblastoma. Nat. Immunol. 20, 1100–1109. doi:10.1038/s41556-019-0343-y

Jong, A. Y., Wu, C. H., Li, J., Sun, J., Fabbri, M., Wayne, A. S., et al. (2017). Large-scale isolation and cytotoxicity of extracellular vesicles derived from activated human natural killer cells. J. Extracell. Vesicles 6, 12493468. doi:10.1080/20436102.2017.1294368

Jung, M. Y., Ababula, A., Brown, D. A., Himes, B. T., Cumba Garcia, I. M., and Parney, I. F. (2022). Superinduction of immunosuppressive glioblastoma extracellular vesicles by IFN-gamma through PD-L1 and IDO1. Neuro Oncol. 24, voad017. doi:10.1093/neuonc/noaad017

Kadry, H., Noorani, B., and Caciolli, L. (2020). A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS 17, 69. doi:10.1186/s1297-020-0230-3

Kucharzewska, P., Christianson, H. C., Welch, J. E., Svensson, K. J., Fredlund, E., Rungner, M., et al. (2013). Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc. Natl. Acad. Sci. U. S. A. 110, 7312–7317. doi:10.1073/pnas.1209998110

Kuleskaya, N., Vítkar, V., Peltola, M., Yegutkin, G. G., Salmi, M., Jalkanen, S., et al. (2013). CD73 is a major regulator of adenosinergic signalling in mouse brain. PLoS ONE 8, e66896. doi:10.1371/journal.pone.0066896

Lapsante, S., Perry, A., and Butowski, N. A. (2018). Primary brain tumours in adults. Lancet 392, 432–446. doi:10.1016/S0140-6736(18)30990-5

Li, X., Zhou, T., Zhu, X., Zhao, F., Yin, L., and Zhou, P. (2006). Effect of hypoxia/reoxygenation on CD37 (ecto-5’-nucleotidase) in mouse microvessel endothelial cells line. Microvasc. Res. 72, 48–53. doi:10.1016/j.mvr.2006.04.005

Lim, M., Xia, Y., Bettgowda, C., and Weller, M. (2018). Current state of immunotherapy for glioblastoma. Nat. Rev. Clin. Oncol. 15, 422–442. doi:10.1038/s41571-018-0033-5

Lindenerberg, M. F. S. and Stoorvogel, W. (2018). Antigen presentation by extracellular vesicles from professional antigen-presenting cells. Annu. Rev. Immunol. 36, 435–459. doi:10.1146/annurev-immunol-041015-055700

Lous, D. N., Perry, A., Wesseling, P., Brutt, D. J., Cree, I. A., Figarella-Branger, D., et al. (2021). The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 23, 1231–1251. doi:10.1093/neuonc/noab106

Lucero, R., Zappulli, V., Sammarco, A., Murillo, O. D., Cheah, P. S., Srivinasan, S., et al. (2020). Glioma-derived miRNA-containing extracellular vesicles induce angiogenesis by reprogramming brain endothelial cells. Cell Rep. 30, 2065–2074. doi:10.1016/j.celrep.2020.01.073

Lucini, L., Cecchetti, S., Huber, V., Luciani, F., Macchia, G., Spadaro, F., et al. (2012). Immune surveillance properties of human NK cell-derived exosomes. J. Immunol. 189, 2833–2842. doi:10.4049/jimmunol.1101988

Luong, N., Lenz, J. A., Modiano, J. F., and Olson, J. K. (2021). Extracellular vesicles secreted by tumor cells promote the generation of suppressive monocytes. ImmunoHorizons 5, 647–658. doi:10.1007/s41598-00000017

Martínez-Lorenzo, M. J., Anel, A., Gamen, S., Monle n, I., Lasierra, P., Larrad, L., et al. (1999). Activated human T cells release biospecific Fas ligand and APO2 ligand in microvesicles. J. Immunol. Baltimore. Md. 150(5) 163, 1274–1281

Mi, Y., Guo, N., Luan, J., Cheng, J., Hu, Z., Jiang, P., et al. (2020). The emerging role of myeloid-derived suppressor cells in the glioma immune suppressive microenvironment. Front. Immunol. 11, 737–811. doi:10.3389/fimmu.2020.00737

Miller, D. K., Ostrom, Q. T., Kruchko, C., Patil, N., Tihan, T., Ciofﬁ, G., et al. (2021). Brain and other central nervous system tumor statistics, 2021. CA Cancer J. Clin. 71, 381–406. doi:10.3322/caac.21693

Gupta, K., Vuckovic, I., Zhang, S., Xiong, Y., Carlsson, B. L., Jacobs, J., et al. (2020). Radiation induced metabolic alterations associated with tumor aggressiveness and poor outcome in glioblastoma. Front. Oncol. 10, 535. doi:10.3389/fonc.2020.00535

Hall, S., Mallaswarathy, D. M., Wei, H., Ebrahimi-Sanaki, S., Stringer, B. W., Day, B. W., et al. (2019). Extracellular vesicles released by glioblastoma cells stimulate normal astrocytes to acquire a tumor-supportive phenotype via p53 and MYC signaling pathways. Mol. Neurobiol. 56, 4566–4581. doi:10.1007/s12035-018-1385-1

Han, S., Feng, S., Ren, M., Ma, E., Wang, X., Xu, L., et al. (2014). Glioma cell-derived placental growth factor induces regulatory B cells. Int. J. Biochem. Cell Biol. 57, 63–68. doi:10.1016/j.biocel.2014.10.005

Hao, C., Parney, I. F., Roa, W. H., Turner, J., Petruk, C. K., and Ramsay, D. A. (2002). Cytokine and cytokine receptor mRNA expression in human glioblastomas:...
(2001). Role of NKG2D in tumor cell lysis mediated by human NK cells: glioblastoma via intercellular transfer of splicing factors. doi:10.1049/jimmunol.1900838

Iturralde, M., et al. (2001). Differential secretion of Fas ligand- or APO2 ligand/TNF-related apoptosis-inducing ligand-carrying microvesicles during activation-induced death of human T cells. J. Immunol. 167, 6736-6744. doi:10.4049/jimmunol.167.12.6736

Nakashima, H., et al. (2018). Immune evasion mediated by PD-L1 on tumors of nonepithelial origin. Clin. Cancer Res. 24, 19, 764. doi:10.1152/ajpcell.00280.2019

Tsutsui, T., Kawahara, H., Kimura, R., Dong, Y., Jiapaer, S., Sabit, H., et al. (2020). Glima-derived endothelial cells promote glioma cells migration via extracellular vesicles-mediated transfer of MTO1C. Biochem. Biophys. Res. Commun. 525, 155–161. doi:10.1016/j.bbrc.2020.02.017

Théry, C., Witwer, K. W., Aikawa, E., Alarçar, M. J., Anderson, J. D., Andriantsitohaina, R., et al. (2018). Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the international society for extracellular vesicles. J. Extracell. Vesicles 7, 19, 764. doi:10.1080/20013078.2018.1535700

Tian, Y., Wang, Z., Wang, Y., Yin, B., Yuan, J., Quan, G., et al. (2020). Glioma-derived endothelial cells promote glioma cells migration via extracellular vesicles-mediated transfer of MTO1C. Biochem. Biophys. Res. Commun. 525, 155–161. doi:10.1016/j.bbrc.2020.02.017

Glioma-derived extracellular vesicles drive tumor progression by conveying tumor-promoting miR-21. J. Extracell. Vesicles 7, 19, 764. doi:10.1080/20013078.2018.1535700

Urabe, F., Kosaka, N., Ito, K., Kimura, T., Egawa, S., and Ochiya, T. (2020). Mitochondria transfer from tumor-activated stromal cells to primary Glioblastoma cells. Mol. Cancer 19, 764. doi:10.1038/s41388-020-0996-3

Vilain, S., Marçais, A., Guimaraes, F. S. F., Loftus, R., Rabilloud, J., Grau, M., et al. (2018). TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci. Signal. 9, r49–r14. doi:10.1126/scisignal.aad1884

Zong, Z., Wang, Z., Wang, Y., Yin, B., Yuan, J., Quan, G., et al. (2020). Glioma-derived endothelial cells promote glioma cells migration via extracellular vesicles-mediated transfer of MTO1C. Biochem. Biophys. Res. Commun. 525, 155–161. doi:10.1016/j.bbrc.2020.02.017

Low et al. 10.3389/fcell.2022.996805
